0
Clinical Investigations: LUNG CANCER |

Clinical Characteristics of Pneumonic-Type Adenocarcinoma of the Lung*

Marie Wislez; Marie-Ange Massiani; Bernard Milleron; Abdelkader Souidi; Marie-France Carette; Martine Antoine; Jacques Cadranel
Author and Funding Information

*From Laboratoire de Biologie Cellulaire et d’Immunopathologie Pulmonaire (Drs. Wislez, Milleron, and Cadranel), UPRES EA 3493, Université Paris VI, UFR Saint-Antoine, Paris; and Services de Pneumologie et de Réanimation Respiratoire (Dr. Massiani and Souidi), et de Radiologie (Dr. Carette), et d’Anatomie Pathologique (Dr. Antoine), AP-HP, Hôpital Tenon, Paris, France.

Correspondence to: Jacques Cadranel, MD, PhD, Service de Pneumologie et de Réanimation Respiratoire, Hôpital Tenon, 4 rue de la chine, 75020 Paris, France; e-mail: jacques.cadranel@tnn.ap-hop-paris.fr



Chest. 2003;123(6):1868-1877. doi:10.1378/chest.123.6.1868
Text Size: A A A
Published online

Purpose: To analyze diagnostic approaches, survival predictors, and treatment efficacy in pneumonic-type adenocarcinoma (P-ADC).

Patients and methods: Fifty-two patients with P-ADC diagnosed between January 1986 and December 2000 were studied. P-ADC was defined as histologically or cytologically proven pulmonary adenocarcinoma with a pneumonia-like consolidation, in a patient with no prior diagnosis of thoracic or extrathoracic adenocarcinoma.

Results: Sixty percent of the patients were men (n = 31), and 65% (n = 34) were current or former smokers. Mean (± SD) age at diagnosis was 66 ± 1.4 years. P-ADC was diagnosed by routine chest radiography in 17% of cases (n = 9). Bronchorrhea was present in 31% of cases (n = 16), and crepitant rales in 58% (n = 30). The primary tumor appeared as consolidations, which could not be assessed and were thus classified Tx, in 83% of the patients (n = 43). Ten percent of the patients (n = 5) had a satellite tumor within the lobe containing the primary tumor (T4), and 63% (n = 33) had a satellite tumor in another lobe (M1). Extrathoracic metastases were present in 5% of cases (n = 3). Bronchial biopsy, transbronchial biopsy, bronchial aspiration, and BAL were positive in 21%, 80%, 44%, and 66% of cases, respectively. The median survival time after diagnosis was 10.5 months (range, 1 to 150 months). The outcome of patients treated by lobectomy or bilobectomy was significantly better than that of patients treated with pneumonectomy, chemotherapy, or best supportive care (p < 0.01). Bronchorrhea and crepitant rales were independent predictors of shorter survival when the treatment modality (surgery vs no surgery) was not entered as a risk factor.

Conclusions: P-ADC is characterized by aerogenous propagation, as emphasized by the results of multivariate analysis showing that bronchorrhea and crepitant rales were the only two independent factors of shorter survival. Surgery remains the most effective treatment in P-ADC, especially when lobectomy is feasible. As CT is not sensitive enough to detect multifocal lesions, new tools are required to evaluate pulmonary involvement and thereby to refine the surgical strategy.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543